Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: G-CSF mobilized CD34+ selected cells for transplantation Clear all
Terminated Phase 2 Interventional Results available

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

NCT03600909
View directory record Official record
Conditions
Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Interventions
Busulfan, Fludarabine, Cyclophosphamide, Anti-Thymocyte Globulin (Rabbit), The CliniMACS device, G-CSF
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
New York, New York • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 5, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation

NCT00859586
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic
Interventions
Miltenyi Magnetic cell sorter for CD3
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
8 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 5, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

NCT01807611
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Total Lymphoid Irradiation, Fludarabine, Cyclophosphamide, Thiotepa, Melphalan, HPC,A Infusion, TC-NK Infusion, G-CSF, Mesna, CliniMACS, Mycophenolate mofetil
Radiation · Drug · Biological + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 5, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

NCT01370213
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Preparative Regimen, NK Cells, Interleukin-2, CD34 Graft/Anti-thymocyte globulin, Donor TCR α/β-depleted Graft/ATG
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 5, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

NCT02143830
View directory record Official record
Conditions
Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Interventions
Busulfan, Cyclophosphamide, Fludarabine, rabbit ATG, G-CSF, Peripheral blood stem cell
Drug · Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
3
States / cities
New York, New York • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 5, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 5, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

NCT00378534
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Miltenyi reagent system, Fludarabine, Cyclosporine, Cyclophosphamide, FILGRASTIM (G-CSF)
Device · Drug · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 5, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders

NCT03093844
View directory record Official record
Conditions
Hematologic Disorders
Interventions
Miltenyi CliniMACS® CD34 Reagent System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 5, 2026, 6:45 AM EDT
No Longer Available No phase listed Expanded access

Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

NCT02258490
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
G-CSF mobilized CD34+ selected cells for transplantation
Biological
Lead sponsor
Emory University
Other
Eligibility
17 Years to 75 Years
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 5, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

NCT03587272
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, low dose total body irradiation, Sirolimus
Drug
Lead sponsor
Robert Nickel
Other
Eligibility
2 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 5, 2026, 6:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Stem Cell Transplantation for Crohn's Disease

NCT00692939
View directory record Official record
Conditions
Crohn's Disease
Interventions
autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG, Melphalan, Thiotepa, Rituximab, Cyclophosphamide, G-CSF, Mesna
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
10 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 5, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

NCT01174108
View directory record Official record
Conditions
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Interventions
Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
Device · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 5, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

NCT02199041
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Cyclophosphamide, Thiotepa, Fludarabine, Melphalan, Mesna, G-CSF, Mycophenolate mofetil, Tacrolimus, Methylprednisolone, Total lymphoid irradiation, Lymphocyte infusions, CliniMACS
Drug · Biological · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 5, 2026, 6:45 AM EDT
Recruiting Phase 3 Interventional

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 5, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders

NCT00587054
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant, Leukemia, Non-Hodgkins, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 5, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

NCT00392782
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 5, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor

NCT00582933
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Allogeneic Marrow Transplant
Interventions
BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 5, 2026, 6:45 AM EDT